- Barrons.com•8 hours ago
Once high-flying biotech stocks like Gilead Sciences (GILD), Celgene (CELG), Regeneron Pharmaceuticals (REGN) and BioMarin (BMRN) have had a tough time during the past 12 months. S&P Global Market Intelligence's Jeffrey Loo sees better times ahead: After the significant outperformance of the biotechnology industry in recent years, 2016 placed biotech investors in unfamiliar territory. In 2015, the FDA approved 45 new drugs, up from 41 in 2014 and 27 in 2013, and the most since a record 53 were approved in 1996.
- GlobeNewswire•10 hours ago
Citi’ s 11 th Annual Biotech Conference September 7 in Boston. Robert W. Baird & Co. 2016 Global Healthcare Conference September 8 in New York. Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology ...
- 24/7 Wall St.•10 hours ago
In a new research report, Baird notes two biotech companies in its research coverage universe that may be considered speculative takeover targets, and a third is a possible target as well.
BioMarin Pharmaceutical Inc. (BMRN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||93.26 x 100|
|Ask||96.00 x 200|
|Day's Range||93.02 - 95.95|
|52wk Range||62.12 - 134.71|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-28.56|
|Avg Vol (3m)||1,906,541|
|Dividend & Yield||N/A (N/A)|